Financial Performance - SpringWorks reported $21.0 million in net product revenue for OGSIVEO in the first full quarter on the market[22, 55] - The company's cash, cash equivalents, and marketable securities totaled $573.0 million as of March 31, 2024[4, 33] - Total operating expenses were $114.9 million for the quarter ended March 31, 2024[55] - Net loss for the quarter was $87.4 million[55] OGSIVEO Commercialization - There are approximately 5,500 to 7,000 U.S desmoid tumor patients actively managed annually[9] - 76% of surveyed oncologists are aware of OGSIVEO and have already used or plan to prescribe it[48] - 82% of oncologists who have used OGSIVEO prefer it to other systemic treatments[48] Mirdametinib Development - Mirdametinib rolling NDA submission for NF1-PN is underway, representing opportunity for a potential second approval by 2025[41] - The company completed a pre-NDA meeting and initiated the rolling NDA submission for mirdametinib[51] Pipeline Expansion - A Phase 1 trial of SW-682 in Hippo mutant solid tumors is planned for initiation in Q2 2024[2, 14] - Initial data from the Phase 2 OvGCT study of nirogacestat is expected in 2H 2024[54]
SpringWorks Therapeutics(SWTX) - 2024 Q1 - Earnings Call Presentation